A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first-line therapy in patients with newly diagnosed, stage I-II extranodal natural-killer/T-cell lymphoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Peng,Sun

第一单位： Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.

作者： Peng,Sun ^[1] ; Yajun,Li ^[2] ; Cong,Li ^[3] ; Kexing,Ren ^[4] ; Yu,Wang ^[5] ; Hang,Yang ^[6] ; Wenqi,Jiang ^[1] ; Liqun,Zou ^[2] ; Haiyan,Yang ^[1] ; Hui,Zhou ^[2] ; Zhi-Ming,Li ^[1]

作者单位： Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China. ^[1] State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. ^[2] Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, 410013, China. ^[3] The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410000, China. ^[4] Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, 310012, China. ^[5] Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China. ^[6]

主题词人类(Humans);淋巴瘤, 结外NK-T细胞(Lymphoma, Extranodal NK-T-Cell);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);脱氧胞苷(Deoxycytidine)

DOI 10.1002/ajh.26922

PMID 36970971

发布时间 2023-06-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交